Open Label, Dose Escalation Study of 4SC-202 in Patients With Advanced Hematologic Malignancies: First-In-Man Study of a Newly Developed, Oral Histone Deacetylase Inhibitor

Trial Profile

Open Label, Dose Escalation Study of 4SC-202 in Patients With Advanced Hematologic Malignancies: First-In-Man Study of a Newly Developed, Oral Histone Deacetylase Inhibitor

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Mar 2016

At a glance

  • Drugs 4SC 202 (Primary)
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Haematological malignancies; Lymphoma; Multiple myeloma; Myelodysplastic syndromes
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Acronyms TOPAS
  • Sponsors 4SC
  • Most Recent Events

    • 21 Mar 2016 Results published in 4SC AG media release.
    • 07 May 2015 According to a 4SC media release, final data report is expected to be published in mid-2015.
    • 31 Mar 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top